Horne AW, Vincent K, Hewitt CA, et al. - The efficacy and safety of gabapentin were examined in women with chronic pelvic pain and no obvious pelvic pathology via performing a multicenter, randomized, double-blind, placebo-controlled trial in 39 UK hospital centers. They randomly assigned 306 women with chronic pelvic pain (with or without dysmenorrhoea or dyspareunia) in a 1:1 ratio to receive gabapentin (titrated to a maximum dose of 2,700 mg daily) or matching placebo for 16 weeks. Despite adequately powered, this study did not reveal significantly lower pain scores in women with chronic pelvic pain in correlation with receiving treatment with gabapentin; further, this treatment was linked with higher rates of side-effects than placebo. Given the rising reports of abuse and evidence of potential harms linked with gabapentin use, they suggest clinicians to consider alternative treatment options to off-label gabapentin for management of chronic pelvic pain and no obvious pelvic pathology.